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Heparin dosing during off-pump CABG
Anticoagulation during off-pump CABG
A B S T R A C T
Objectives: Levels of anticoagulation during off-pump coronary artery bypass grafting (OPCAB) remain
controversial. Prolonged activated clotting time (ACT) during OPCAB increases blood loss during surgery
and can also cause paradoxical increase in postoperative myocardial infarction. Shorter ACT can increase
thrombotic complication. Maintaining a steady ACT level is challenging. We have used continuous
heparin infusion after initial bolus during OPCAB to maintain a steady low target ACT. The objective of
the present study was to assess the effectiveness and safety of heparin infusion in maintaining a steady
target ACT level.
Methods: This was a prospective study of consecutive OPCAB patients. ACT was measured after initial
bolus dose of heparin. Once ACT of more than 200 seconds was achieved, heparin infusion was started to
maintain the required level of anticoagulation. CPK-MB was measured in operation room, 6 and 24 hours
postoperatively to rule out ischemic complication.
Results: ACT could be maintained in target range with heparin infusion in 80.1% patients (161/201). Of
the 40 patients with one or more ACT reading less than 200 seconds, 38 patients were managed by
increasing the dose of heparin infusion and only 2 patients required additional bolus dose of heparin.
Conclusions: Heparin infusion maintains a steady target ACT level and avoids peaks and troughs
associated with bolus doses. Lower level of anticoagulation using continuous heparin infusion does not
increase ischemic complications. This is the ﬁrst ever study of use of heparin infusion during OPCAB. We
may conclude that heparin infusion is a safe anticoagulation strategy for OPCAB.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Off-pump coronary artery bypass grafting (OPCAB) is an
established method of surgical revascularization. The various
techniques of OPCAB continue to evolve. Optimum anticoagulation
during OPCAB remains elusive, variable, and debatable.1 Level of
anticoagulation during OPCAB is measured by ACT (activated§ Meeting presentation: Presented in the Annual Scientiﬁc Meeting ISMICS held
in Berlin 2015 with the heading ‘‘Heparin Infusion During Off-Pump Coronary
Artery Bypass Grafting Safely Maintains Steady Level of Anticoagulation’’ and was
judged as the best paper in coronary revascularization category.
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0019-4832/ 2016 Cardiological Society of India. Published by Elsevier B.V. This is an
licenses/by-nc-nd/4.0/).clotting time). It is generally believed by the cardiac surgeons that
longer ACT is better for graft patency and shorter ACT during
OPCAB may cause graft blockage. This belief is arbitrarily
extrapolated from experience of conventional coronary artery
bypass grafting (CABG) using cardiopulmonary bypass and is
without any evidence. So there is wide variability in the initial
heparin dose, subsequent heparin doses, and target ACT level
during OPCAB from center to center across Europe2,3 and United
states.1 There is no established guideline about the heparin dosing
and level of anticoagulation to be maintained during OPCAB. This
has resulted in empirical protocols being used during OPCAB.2 No
differences in coagulation indices were detected during OPCAB
using high and low dose heparin.4 But there is no study about
OPCAB graft patency with different levels of anticoagulation.5
Anticoagulation strategy during OPCAB is arbitrarily derived from
experience of coronary artery bypass using cardiopulmonary open access article under the CC BY-NC-ND license (http://creativecommons.org/
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absent during OPCAB.
Physiology of OPCAB is different from CABG using cardiopulmo-
nary bypass and probably similar to percutaneous coronary
intervention (PCI). It is well established that ACT more than
350 seconds is detrimental to stent patency during PCI paradoxically
due to platelet activation.6 Recent OPCAB study suggests that longer
than 350 seconds of ACT during OPCAB is associated with
signiﬁcantly higher incidence of postoperative myocardial infarc-
tion.7 Maintaining a shorter ACT level during OPCAB may have an
added beneﬁt of minimizing blood loss during the procedure.7,8 ACT
more than 400 seconds was maintained in OPCAB group in recently
published Danish off-pump versus on on-pump revascularization
(DOOR) study. It was concluded by the authors of DOOR study that
higher level of anticoagulation during OPCAB may result in increased
bleeding without improving graft patency.8,9
Maintaining low steady ACT is challenging as any further drop in
ACT may result in thrombus formation leading to unwanted graft
blockage. This is particularly true during a prolonged procedure. This
apprehension of thrombus formation may lead to higher heparin
doses resulting in prolonged ACT. The conventional method of
heparin dosing is initial bolus and followed by intermittent bolus
doses to maintain ACT above a predetermined target value. This
practice is mostly derived from conduction of cardiopulmonary
bypass where ACT is maintained above 480 seconds. A little higher
dose is considered harmless as higher ACT induced bleeding can
easily be managed since blood from operative ﬁeld is returned using
cardiotomy suction. Moreover, intermittent bolus doses result in
peaks and trough which may be unwanted during OPCAB. We have
used continuous heparin infusion after initial bolus dose during
OPCAB to maintain a steady low target ACT. Our target ACT was
between 200 and 300 seconds in this study. The objective of the
present study is to assess the effectiveness and safety of heparin
infusion in maintaining a steady target ACT level.
2. Patients and methods
The study was conducted in accordance with the principles of
the declaration of Helsinki. All cases of consecutive unselected
isolated off pump coronary artery bypass grafting (OPCAB)
operated by the ﬁrst author were included in this prospective
study. Heparin is used as anticoagulant during OPCAB. We used
initial bolus dose to achieve target ACT above 200 seconds. After
this target level is achieved, we used heparin infusion instead of
intermittent bolus doses. Heparin is used as infusion in all clinical
conditions. This study had used the conventional method of
heparin administration as infusion during OPCAB and hence no IRB
approval was obtained.
3. Anticoagulation protocol during OPCAB
Initial heparin bolus dose: 100 units/kg of heparin (heparin
sodium) is used as bolus – 25% of this is given before disconnecting
the internal mammary artery and the remaining 75% is given
before initiation of bypass grafting procedure. ACT was checked
5 minutes after the total 100 units/kg heparin dose. Blood samples
were always collected from arterial line for ACT measurement. We
targeted an ACT of more than 200 seconds after bolus dose. If
target ACT is not achieved, additional dose of heparin is given to
achieve ACT > 200 seconds. We used heparin vial of 25,000 units
in 5 ml in all cases. Out of this, 10,000 units were diluted in 10 ml
(1000 units/ml). This solution was used for bolus doses.
Heparin infusion: After target ACT of more than 200 seconds was
achieved, heparin infusion was started. Heparin infusion was
prepared by mixing 10,000 units of heparin diluted in total volume
50 ml in a syringe with concentration of 200 units per ml. Heparininfusion was administered using syringe pump through central
line. Dose of heparin infusion was adjusted according to ACT of the
patient. ACT was measured every hour. Infusion was stopped after
the last distal anastomosis was completed. Total amount of
heparin used was calculated and 50% of the total heparin dose was
reversed using protamine. Additional dose protamine was used
only if post-protamine ACT was not normalized.
Monitoring thrombotic complication: The surgical team was
vigilant and looked for clots in the operating ﬁeld. If a clot was
detected, it was informed to the anesthetist, ACT measurement was
repeated, and bolus dose of heparin was given if required. CPK-MB
was measured in operation room, 6 and 24 hours postoperatively to
rule out ischemic complication due to bypass graft dysfunction.
Data analysis: Heparin dosing and ACT was recorded prospec-
tively. Change in ACT was calculated as positive if ACT increased and
negative if ACT decreased. After data collection, data analysis was
done with the help of PSPP Software. Quantitative variables were
presented with mean and standard deviation. Correlation among
various study parameters was assessed with Pearson’s correlation
coefﬁcient. Qualitative data was presented as frequency and
percentage tables, and P value <0.05 was taken as level of
signiﬁcance.
4. Results
An initial bolus dose of 100 unit/kg was adequate in 185 (92%)
patients to achieve ACT more than 200 seconds. Remaining
16 patients required additional bolus dose to achieve initial ACT
more than 200 seconds. Figs. 1 and 2 show the correlation between
the heparin dose and ACT.
After ACT more than 200 seconds was achieved, heparin infusion
was started to maintain ACT between 200 and 300 seconds. Figs.
3 and 4 show the change in ACT with different doses of heparin
infusion. There was wide variation among patients in the heparin
dose required to maintain the target ACT. Infusion dose of 40 units/
kg of body weight/hour maintained almost the same ACT, lower
doses decreased and higher doses increased ACT. In 80.1% patients
(161/201), ACT was maintained in target range with heparin
infusion. Of the 40 patients with one or more ACT reading less than
200 seconds, 38 patients were managed by increasing the dose of
heparin infusion and only 2 patients required additional bolus dose
of heparin. One patient in our series had signiﬁcant CPK-MB rise
postoperatively in spite of ACT being higher than desired level. He
had diffuse coronary artery disease and required mid and distal LAD
endarterectomy. As the ACT level was higher than desired level and
patient had mid and distal endarterectomy, this CPK-MB rise cannot
be attributed to inadequate level of anticoagulation.
5. Discussion
OPCAB techniques continue to evolve in India in spite of
widespread skepticism about the long-term result of OPCAB.10
Coronary artery bypass grafting is a palliative procedure and
effectiveness of the procedure is directly proportional to graft
patency. To improve graft patency the target activated clotting time
is maintained between 250 and 300 seconds in India11 But there is
no study of peri-operative myocardial infarction rate with this target
ACT level between 250 and 300 seconds. Wide variation in ACT level
maintained during OPCAB is reported from different parts of the
world.1–3 A study from Korea revealed that ACT more than
350 seconds are associated with paradoxically higher incidences
of peri-operative myocardial infarction.7 In DOOR study, ACT longer
than 400 seconds was maintained in OPCAB group and may have
resulted in higher rate of vein graft failure due to paradoxical platelet
activation.8 Prolonged ACT increases blood loss during OPCAB
without improving graft patency.9 The physiology of OPCAB is
Fig. 2. Correlation between initial bolus dose of heparin in units per kg of body weight and ACT 5 minutes after the bolus dose.
Fig. 1. Correlation between initial bolus dose of heparin in units and ACT 5 minutes after the bolus dose.
Fig. 3. Correlation between infusion rate of heparin in units per kg of body weight per hour and change of ACT.
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Fig. 4. Correlation between infusion rate of heparin in units per kg of body weight per hour and change of ACT in percentage.
K.K. Saha et al. / Indian Heart Journal 68 (2016) 798–802 801different from coronary artery bypass grafting using cardiopulmo-
nary bypass and probably similar to PCI.12
Longer ACT (more than 350 seconds) is avoided during PCI as it
does not increase stent patency rate but increases bleeding
complications. Similarly in DOOR study, ACT more than 400 sec-
onds in the OPCAB group may have caused increased bleeding
without improving graft patency.8,9 It may be concluded that ACT
less than 350 seconds (between 200 and 300 seconds) may be
optimal for OPCAB with least incidence of postoperative myocar-
dial infarction and minimal intra-operative blood loss.12
The conventional method of heparin dosing is initial bolus and
followed by intermittent bolus doses to maintain ACT above a
predetermined target value.11 This practice is mostly derived from
conduction of cardiopulmonary bypass where ACT is maintained
above 480 seconds and a little higher heparin dose is considered
harmless. Higher ACT-induced bleeding can easily be managed as
blood from operative ﬁeld is returned using cardiotomy suction. It
is possible that cardiopulmonary bypass-induced coagulopathy
has protective effects from heparin-induced platelet activation at
the level of ACT maintained during the procedure. However, during
OPCAB, such protective effect is absent. So during OPCAB,
prolonged ACT level may result in paradoxical increase in
postoperative myocardial infraction.7
Heparin has a short half life which may vary with dose and from
patient to patient. Half life of heparin increases with dose when
administered as bolus. The disappearance of anticoagulant activity
of heparin follows nonlinear kinetics – combination of saturable
and linear mechanism. There is a threshold below which heparin
level rises only slowly and above which rises rapidly in a linear
fashion correlating with dose.13 Biological half life of heparin
increases from 30 minutes after a dose of 25 units/kg IV bolus to
60 minutes with IV bolus dose of 100 units/kg and 150 minutes
with bolus dose of 400 units/kg.14 The problem with intermittent
supplemental dosing of heparin is that if a patient has a short half
life, the ACT level may fall below the critical level of 200 seconds.
This may lead to thrombus formation leading to graft blockage. So
the normal response to a lower ACT is to supplement a higher dose
of bolus heparin. Higher dose of heparin may increase the heparin
half life with increase of ACT above 350 seconds with detrimental
effects on graft patency due to platelet activation.8,9,12
In the protocol of heparin infusion adopted by us, it is clearly
demonstrated that it is possible to achieve a steady ACT level with
heparin infusion. Initial dose of 100 units/kg was adequate in mostpatients to achieve ACT more than 200 seconds. Infusion dose of
40–50 units/kg/h was adequate to maintain the desired ACT level.
Higher infusion dose was used to increase the ACT and vice versa.
Moreover, even when ACT dropped to less than 200 seconds, there
was no clot formation in the operative ﬁeld. In such situation, we
increased the infusion rate to increase ACT. Bolus doses were given
in two patients when clot formation was detected in the operating
ﬁeld. Desired level of ACT can be achieved using dose of infusion
appropriate for the patient. There is wide variability in heparin
dose requirement among the patients to maintain target level of
ACT between 200 and 300 seconds. It is easier to ﬁne tune infusion
as there is a very minimal risk of ACT dropping below 200 seconds
with infusion on-ﬂow. So heparin infusion has resulted in minimal
overshooting of ACT in the non-responders.
Study limitations: Several limitations of this study must be
recognized. There is no control group in this study. This infusion
regime is not compared with intermittent bolus doses of heparin.
Moreover, long-term graft patency of such anticoagulation
strategy is to be determined by further study. We did not collect
the blood loss data prospectively in these patients.
Conclusion: Level of anticoagulation during OPCAB is often
neglected. Higher level of anticoagulation is often considered
better for OPCAB graft patency but higher level of anticoagulation
may lead to paradoxical increase in thrombotic complication.8 In
our series of 201 consecutive OPCAB patients, one patient had
postoperative CPK MB rise in spite of ACT being more than the
desired level. He had diffuse coronary artery disease and required
mid and distal LAD endarterectomy. This study proves that lower
level of anticoagulation (ACT between 200 and 300 seconds) is safe
and does not increase ischemic complications. Low steady level of
target ACT can be maintained using heparin infusion. Heparin
infusion also avoids peaks and troughs associated with bolus doses.
Heparin is conventionally used as continuous infusion in
various clinical conditions. It has a short half-life so it is
pharmacologically correct to use heparin infusion to maintain
target ACT after a bolus dose to achieve the target level of
anticoagulation. Added advantage of maintaining shorter ACT is
reduction in blood loss. In our experience, this regime is safe and
effective in maintaining desired level of anticoagulation precisely
with no apparent downside. This is the ﬁrst ever study of use of
heparin infusion during OPCAB. We can conclude that heparin
infusion is a safe and optimum anticoagulation strategy for OPCAB
to maintain precise anticoagulation level.
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